-
Mashup Score: 100
Jean M. Connors, MD, Dana-Farber Cancer Institute and Amy E. DeZern, MD, MHS, Johns Hopkins University No relevant conflicts of interest to declare. This highly anticipated session highlights the Joint Program Committees’ selections of the highest-impact abs tracts, featuring substantive, novel, and groundbreaking data that were not available by the general abstract submission deadline and would otherwise not be presented at the ASH annual
Source: ash.confex.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 0Webprogram Unavailable - 2 month(s) ago
Please click HERE if you are not redirected in 5
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Multiomics Profiling of Measurable Residual Disease (MRD) for Understanding the Biology of Ultra-Drug Resistance in Multiple Myeloma (MM) [Dec 10, 2022] @camilagdeblois et al. Abst 99 #ASH22 https://t.co/izMBdiswlP #mmsm #mmMRD https://t.co/Pqd9dhwohw
-
-
Mashup Score: 0Webprogram Unavailable - 2 month(s) ago
Please click HERE if you are not redirected in 5
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Global Treatment Standard in Multiple Myeloma Remains Elusive: Updated Results from the INSIGHT MM Global, Prospective, Observational Study [Dec 10, 2022] @NoemiPuigM et al. @BerdejaJesus Abs 1859 #ASH22 https://t.co/mCCkPgMebV #mmsm #globonc https://t.co/JkTBMSg0au
-
-
Mashup Score: 0Frontline ibrutinib for younger patients with MCL: Results from the phase III TRIANGLE trial - 3 month(s) ago
During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, Martin Dreyling presented results from the phase III TRIANGLE trial as part of the plenary scientific session.
Source: lymphomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
@timfenske Check the TRIANGLE trial results presented at #ASH22 here: https://t.co/F4m1zulFjO #lymsm #soho2023
-
-
Mashup Score: 3Variability of definition of high‐risk multiple myeloma across phase III clinical trials - 3 month(s) ago
eJHaem is a Gold open access haematology journal of the British Society for Haematology, publishing practice and research papers applicable to a worldwide readership.
Source: onlinelibrary.wiley.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Proud of @FZanouneh who worked hard to get to this step and as a student published and was awarded in #ASH22 #Match2024 #MedTwitter His paper he led on Variability of definition of high-risk multiple myeloma across phase III clinical trials https://t.co/wiM8wDXc14 Good luck https://t.co/pSkPTGuvdv
-
-
Mashup Score: 0Ajai Chari, MD, Discusses the MonumenTAL-1 Study - 4 month(s) ago
Talquetamab “demonstrated robust effic acy and manageable safety” in patients with heavily pretreated relapsed or refractory multiple myeloma, according to results from the phase I/II MonumenTAL-1 study. Ajai Chari, MD, of Mount Sinai School of Medicine, presented the data on talquetamab, a bispecific antibody targeting CD3 and GPRC5D, during the 2022 American Society of Hematology (ASH) Annual Meeting. “The MonumenTAL-1 study is really exciting,” Dr. Chari said, noting the phase I portion of the study
Source: www.bloodcancerstoday.comCategories: Latest Headlines, Partners & KOLsTweet-
Looking back at MounmenTAL-1? Don't miss our previous coverage of the talquetamab data presented at #ASCO2023 and #ASH22! In this video interview, @AjaiChari of @UCSF speaks about the results he presented at #ASH22. 📺https://t.co/G87ZRythZ4 #mmsm https://t.co/7Bzn4YpL1s
-
-
Mashup Score: 2
This provides reassurance that long-term lenalidomide treatment is safe and associated with improved outcomes in TE and TNE populations, although monitoring for SPM development should be incorporated into clinic review processes.
Source: www.thelancet.comCategories: Latest Headlines, Partners & KOLsTweet-
🇬🇧 Myeloma XI trial does it again! #ASH22 update in @eClinicalMed about outcomes of maintenance len in #MMsm. Similar conclusion to @CIBMTR data by @BKRagonMD et al: while SPMs occur, MM >10x likely as cause of death - len remains important tool. https://t.co/SevkXdXd3R https://t.co/u2eXuAPClW
-
-
Mashup Score: 02023 ASH ALL Inotuzumab Update [Slides] - Van Huynh, MD MOASC - 4 month(s) ago
Inotuzumab, GMALL, Ponatinib & Blinatumomab ASH Updates in Acute Lymphoblastic Leukemia By Van Huynh, MD Updates in acute lymphoblastic leukemia that was presented at ASH in New Orleans. So I think there were so many great talks. There were so many great talks and I decided I would focus on just three and really…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🚀 #ASH22 Updates in ALL Immunotherapy with Inotuzumab! Van Huynh, MD @MOASC_Office @UCIrvineHealth, shared insights at #MOASC23. 🩺 Discover remarkable breakthroughs![Video]🎥: https://t.co/BBlUqPvBAS 💊 #oncology #leukemia #medicalresearch #Immunotherapy #UCIMedSchool #CARTcell https://t.co/OSKdxJCTLI
-
-
Mashup Score: 1Elranatamab for RRMM: Updates from the MagnetisMM trials - 4 month(s) ago
Here, we summarize the latest data from the MagnetisMM trials of elranatamab for relapsed/refractory multiple myeloma in both BCMA-exposed and BCMA-naïve patients.
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Read our summary of the latest updates from the MagnetisMM trials of elranatamab for RRMM, including BCMA-exposed and -naïve patients. 👉 https://t.co/lSjsc75K3S #EHA2023 #ASCO23 #ASH22 #mmsm #myeloma https://t.co/B6YsmetQRN
-
-
Mashup Score: 0TRIANGLE Trial Results Support First-Line Ibrutinib Use in MCL - 4 month(s) ago
High-dose cytarabine-containing immunochemotherapy followed by autologous hematopoiet ic stem cell transplantation (AHSCT) “failed to show superiority over” an ibrutinib-containing treatment without AHSCT in patients with mantle cell lymphoma, according to results from the phase III TRIANGLE trial. Martin Dreyling, MD, of the LMU University Hospital Munich in Germany, and colleagues conducted the study and presented its results at the 2022 American Society of Hematology Annual Meeting. The European MCL
Source: bloodcancerstoday.comCategories: Latest Headlines, Partners & KOLsTweet-
Need a refresher on the TRIANGLE study? Check out our coverage from #ASH22: https://t.co/ol6Nrfj7OK https://t.co/YFxGbrmIA6
-
Dara RVd superior to RVd for PFS in newly diagnosed transplant eligible myeloma! #ASH22 As of now any randomized trials using triplets as control arm in newly diagnosed transplant eligible myeloma is unfair to patients. Late-Breaking Abstracts https://t.co/oiQ8dwcPCc